Compare RKDA & ENSC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RKDA | ENSC |
|---|---|---|
| Founded | 2002 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Agricultural Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9M | 1.7M |
| IPO Year | 2015 | N/A |
| Metric | RKDA | ENSC |
|---|---|---|
| Price | $0.67 | $0.30 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 4.9M | 947.2K |
| Earning Date | 05-07-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 66.92 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $4,858,000.00 | N/A |
| Revenue This Year | $61.67 | $55.01 |
| Revenue Next Year | N/A | $1,033.97 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.65 | $0.23 |
| 52 Week High | $6.71 | $2.75 |
| Indicator | RKDA | ENSC |
|---|---|---|
| Relative Strength Index (RSI) | 29.97 | 52.04 |
| Support Level | N/A | $0.23 |
| Resistance Level | $1.51 | $0.32 |
| Average True Range (ATR) | 0.16 | 0.02 |
| MACD | -0.02 | 0.01 |
| Stochastic Oscillator | 1.60 | 69.47 |
Arcadia Biosciences Inc is a company with science-based approaches to develop high value products and drive innovation in the consumer goods industry. The company has one operating and reportable segment, which derives revenue from the sale of Zola coconut water. The company's consumer brands in the food, beverage, and body care categories, and others. Its products include: Zola Coconut Water, and Agronomic Wheat Traits. Geographically, the company operates in United States, Argentina, India, and Canada. It derives maximum revenue from United States.
Ensysce Biosciences Inc is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. The company is developing a new class of powerful, tamper-proof opioids that prevent both drug abuse and overdoses. Its products are anticipated to provide safer options to treat severe pain and assist in preventing deaths caused by opioid abuse, reducing human and economic costs. The company's current development pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, theTrypsin Activated Abuse Protection, or the TAAP platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant, or the MPAR platform. The Company currently operates in one business segment, which is pharmaceuticals.